

1 **Title**

2 A modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination analysis

3

4 **Short title**

5 COVID-19 impact on HPV vaccination

6

7 **Authors**

8 Louiza S Velentzis<sup>1,2‡</sup>, Megan A Smith<sup>1‡\*</sup>, James Killen<sup>1</sup>, Julia Brotherton<sup>2,3</sup>, Rebecca Guy<sup>4</sup>, Karen Canfell<sup>1</sup>

9

10 ‡Joint first authors

11

12

13 1. Daffodil Centre, The University of Sydney, a joint venture with CCNSW, Sydney Australia;

14 2. School of Population and Global Health, University of Melbourne, Victoria, Australia

15 3. Australian Centre for Prevention of Cervical Cancer, Melbourne, Victoria, Australia

16 4. The Kirby Institute, University of New South Wales, Sydney, Australia

17

18

19 \*Corresponding author

20 A/Prof Megan A Smith, PhD

21 The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Australia.

22 [Megan.Smith@nswcc.org.au](mailto:Megan.Smith@nswcc.org.au)

23 T:+61293341445

24 **Abstract**

25  
26 COVID-19 disrupted school attendance in many countries, delaying routine adolescent vaccination against  
27 human papillomavirus (HPV) in some settings. We used the '*Policy1-Cervix*' HPV model (natural  
28 history/vaccination/screening/HPV-related cancers), to estimate the impact on HPV-related cancers from  
29 disruptions to HPV vaccination in a high-income setting. Compared to no disruption (nonavalent vaccine  
30 uptake, age 12 [females:82.4%; males:75.5%] as in Australia), additional lifetime HPV-related cancer cases were  
31 calculated for three disruption scenarios affecting one birth cohort (2008): i) 1-year delay (no doses missed); ii)  
32 1 to 7-year delay (slow catch-up); iii) no catch-up (herd effects only). A fourth scenario assumed no catch-up for  
33 two cohorts (2008,2009). We found a 1-year delay could result in  $\leq 0.3\%$  more HPV-related cancers ( $n=4$ ) but  
34 the increase would be greater if catch-up was slower (5%;  $n=70$ ), and especially if there was no catch-up (49%;  
35  $n=750$ ). Additional cancers for a single missed cohort were most commonly cervical (23%), oropharyngeal  
36 (males:20%) or anal (females:16%). In the worst-case scenario of two cohorts missing vaccination,  $\leq 62\%$  more  
37 HPV-related cancers would be diagnosed ( $n=1,892$ ). In conclusion, providing catch-up of missed HPV vaccines is  
38 conducted, short-term delays in vaccinating adolescents are unlikely to have substantial long-term effects on  
39 cancer.

## 40 Introduction

41 Australia was the first country to implement a fully-government funded National HPV Vaccination program.  
42 HPV vaccination has been routinely offered through schools, to girls aged 12–13 years since 2007 and to boys  
43 aged 12-13 years since 2013 (plus catch-up for females aged 14 to 26 years in 2007-2009 and for males age 14-  
44 15 in 2013-2014). In 2018, a three-dose schedule with the quadrivalent HPV vaccine which protects against  
45 four HPV types (6, 11, 16 and 18), was replaced by a two-dose schedule with the nonavalent HPV vaccine  
46 (HPV9), protecting against an additional five oncogenic HPV types (31, 33, 45, 52 and 58). Since 2017, free  
47 catch-up of vaccinations under the Australian National Immunization Program, including the HPV vaccine, is  
48 available to all people aged under 20 years and is administered in primary care.<sup>1</sup> HPV course completion rates  
49 by age 15 were 79.8 % among girls and 77.0% among boys who reached the age of 15 years in 2019.<sup>2</sup>

50  
51 Following the World Health Organization’s declaration of the COVID-19 pandemic in March 2020, strict national  
52 and state-level infection control measures were introduced in Australia. Social and physical restrictions  
53 affected essential health services including the delivery of school-based vaccination programs due to school  
54 closures from imposed lockdowns in 2020 and in some states in 2021.<sup>3,4</sup> Globally, the World Health  
55 Organization reported the largest continued decline in overall vaccinations in the last three decades and a loss  
56 of over a quarter of the HPV vaccine coverage achieved in 2019.<sup>5</sup>

57  
58 Infection with oncogenic HPV types is a major causal factor for the development of cervical cancer and for a  
59 fraction of cancers of the anus, oropharynx, penis, vagina, and vulva.<sup>6</sup> Except for cervical screening, organized  
60 screening is not generally available for any of the other HPV-related cancers. A previous analysis of the burden  
61 of HPV-related disease in Australia estimated that 80% of the estimated 1,544 HPV-associated cancers in 2012  
62 were attributable to types preventable by the quadrivalent vaccine (HPV16/18), with an additional 9%  
63 attributable to the five additional types prevented by the nonavalent vaccine.<sup>7</sup>

64  
65 The aim of this study was to estimate the additional lifetime HPV-related cancer cases in men and women that  
66 could be caused by HPV vaccination delays or missed doses due to the pandemic by using a simulation model  
67 to project the long-term outcomes from different potential disruption scenarios, using Australia as an example.  
68 The study was designed prior to the emergence of actual 2020-21 vaccination disruption data, and hence, a  
69 number of potential disruption scenarios were considered to encompass a wide range of possibilities.

70

## 71 Methods

### 72 *Model*

73 We used Policy1-Cervix, an established modelling platform of dynamic HPV transmission, HPV natural history,  
74 cervical screening, treatment and cancer survival that has been validated across several settings. The dynamic  
75 HPV transmission component of Policy1-Cervix incorporates HPV vaccination and was used to estimate HPV  
76 incidence by age under scenarios of disruption to vaccination coverage compared to a no disruption scenario.  
77 The number of lifetime cervical cancer cases was subsequently estimated for the cohorts affected after  
78 explicitly modelling cervical screening (5-yearly HPV screening starting from age 25)<sup>8</sup> to take into account that  
79 cervical screening may prevent some cancers that would otherwise have been prevented by vaccination. In  
80 addition, HPV incidence estimated by the dynamic HPV transmission model was used in a separate incidence-  
81 based model to project the lifetime number of non-cervical HPV-related cancers in both sexes (i.e., anal,  
82 oropharyngeal, penile, vaginal, vulvar), as previously described.<sup>9</sup> Data included age- and sex-specific incidence  
83 of each cancer and proportion of cases attributable to vaccine-targeted HPV types (Supplementary Files 1A, 1B,  
84 1C). In a sensitivity analysis, we also used an analogous incidence-based approach to also estimate the impact  
85 on cervical cancer, rather than explicitly allowing screening to prevent some of the cervical cancers which

86 would arise due to missed vaccination. Further information on the Policy1-Cervix model can be found at  
87 <https://www.policy1.org/models/cervix/documentation>.

88  
89 *Scenarios*  
90 A baseline scenario of uninterrupted HPV vaccination (status quo) assumed a 2-dose uptake of HPV9 at age 12  
91 of 82.4% among females and 75.5% among males. Three disruption scenarios were modelled affecting the 2008  
92 birth cohort who were aged 12 in 2020 (322,115 people). Scenario 1 assumed a fast catch-up where  
93 vaccination was delayed by one year (but no doses were entirely missed); scenario 2 assumed a slow catch-up  
94 where vaccination was delayed between 1 and 7 years with an equal proportion being caught up each year;  
95 and scenario 3 assumed there was no catch-up, and therefore any protection in the cohort would be due to  
96 herd effects only. A fourth scenario was also conducted which assumed disruption to HPV vaccination for two  
97 birth cohorts (cohort of 2008 and 2009) (644,230 people), with no catch-up.

98  
99 For each scenario we estimated the number of HPV-associated cancer cases (from age 12 to 84 years)  
100 prevented by vaccination compared to an unvaccinated comparator cohort, and the additional number of cases  
101 under each disruption scenario compared to the no disruption scenario.

102

## 103 **Results**

104 In the baseline scenario, we estimate 2,583 HPV-related cancer cases would be prevented in the 2008 cohort  
105 due to HPV vaccination, equating to 63% of all HPV-related cases (Table 1). The first disruption scenario (1-year  
106 delay) would result in 4 (0.3%) additional lifetime cancer cases and slightly fewer cases prevented overall  
107 (2,579). Under a slow vaccination catch-up strategy or in the worse cases - no vaccination catch-up for either  
108 one or two cohorts - an additional 70 (5%), 750 (49%) and 1892 (62%) cancer cases, respectively, were  
109 predicted to occur.

110  
111 Table 2 shows a breakdown of HPV-related cancer cases developed over a lifetime by cancer type and sex for  
112 the disruption scenarios. In the worst-case scenarios of missed HPV vaccination, most of the additional cancers  
113 occurred in females, and the additional cancers were most commonly cervical and anal cancers (females) and  
114 oropharyngeal, followed by anal cancers (males). When combined across both sexes, the additional cancers  
115 were most commonly oropharyngeal (>80% of which were in males) and anal cancers (mostly in females).  
116 In the main analysis, we explicitly modelled primary HPV cervical screening as also occurring in these cohorts,  
117 which would allow the cervical screening program to compensate, to some extent, for cervical cancers not  
118 prevented via HPV vaccination. In the sensitivity analysis that used an incidence-based approach, the number  
119 of additional cervical cancer cases predicted was larger and cervical cancers would have comprised around 35%  
120 of the additional HPV-related cancer cases (rather than around 17-25%, when screening was modelled)  
121 (Supplementary File 1D). The percentage increase in cases was similar but somewhat higher (for example 54%  
122 increase in cases for one missed cohort, compared to 49% increase when screening was modelled).

123 **Table 1: Estimated number of HPV-related cancer cases and cases prevented for vaccinated and unvaccinated cohorts, and four vaccination**  
 124 **disruption scenarios.**

125

Modelled scenarios	Affected Cohort (2008)					Affected Cohorts (2008 and 2009)				
	Total Cases	Prevented Cases (Unvax Comparator)	Additional Cases (Compared to No disruption)	% Prevented (Unvax Comparator)	% Additional (Compared to No disruption)	Total Cases	Prevented Cases (Unvax Comparator)	Additional Cases (Compared to No disruption)	% Prevented (Unvax Comparator)	% Additional (Compared to No disruption)
Unvaxed	3,923					7,847				
No disruption	1,532	2,583		63%		3,061	4,876		63%	
S1: 1 y delay	1,537	2,579	4	63%	0.3%	3,066	4,781	5	63%	0.2%
S2: 1 to 7y delay	1,603	2,513	70	61%	5%	3,133	4,714	72	62%	2%
S3: no catch-up	2,282	1,833	750	45%	49%	3,846	4,001	785	53%	26%
S4: no catch-up (2 missed cohorts)	2,503	1,613	970	39%	63%	4,954	2,893	1892	40%	62%

126 Abbreviations: vax: vaccine; unvaxed: unvaccinated (i.e. assuming no HPV vaccination in cohort(s)).

127 No disruption: status quo HPV vaccination in males and females at age 12; scenario 1: rapid catch-up, 1-year delay in HPV vaccine catch-up; scenario 2: slow catch-up, 1 to 7-year delay in


128 HPV vaccine catch-up; scenario 3: no HPV vaccine catch-up (herd effects only 2008 cohort); scenario 4: no HPV vaccine catch-up (herd effects only; 2008 and 2009 cohorts).

129 **Table 2: Estimated number of cancer cases in modelled scenarios according to sex and cancer type.**

Modelled scenarios	Total Cases (additional compared to no disruption)	Females, N (additional compared to no disruption)					Males, N (additional compared to no disruption)		
		Anal	Cervical	Oropharyngeal	Vaginal	Vulvar	Anal	Oropharyngeal	Penile
<b>2008 cohort</b>									
Unvaxed	3,923	489	788	185	162	729	389	911	271
No disruption	1,532	100	62	86	61	580	74	423	146
Scenario 1	1,537 (4)	101 (1)	63 (1)	86	61	580	75 (1)	424 (1)	146
Scenario 2	1,603 (70)*	114 (14)	74 (12)	90 (4)	64 (3)	586 (6)	85 (11)	440 (17)	150 (4)
Scenario 3	2,282 (750)*	236 (136)	250 (188)	121 (35)	96 (35)	632 (52)	175 (101)	593 (170)	180 (34)
<b>2008 and 2009 cohorts</b>									
Unvaxed	7,847	978	1,576	370	324	1458	778	1822	542
No disruption	3,061	199	125	172	122	1160	148	845	292
Scenario 4									
2008 cohort	2,503 (971)*	276 (176)	303 (241)	131 (45)	107 (46)	647 (67)	205 (131)	644 (221)	190 (44)
2009 cohort	2,451 (922)	268 (169)	285 (222)	129 (43)	104 (43)	644 (64)	199 (125)	634 (212)	188 (42)
Scenario 4 total	4,954 (1,892)*	544 (345)	588 (463)	260 (88)	211 (89)	1,291 (131)	404 (256)	1,278 (433)	378 (86)

130  
131 \*The number of additional cases presented in the table do not always match the difference between case figures stated for individual scenarios in table 2, due to rounding.  
132 Unvaxed: assuming no HPV vaccination in cohort (s); No disruption: HPV vaccination in males and females at age 12 with coverage of 82.4% in females and 75.5% in males; scenario 1:  
133 rapid catch-up, 1-year delay; scenario 2: slow catch-up, 1 to 7-year delay; scenario 3: no catch-up (herd effects only 2008 cohort); scenario 4: no catch-up (herd effects only; 2008 and  
134 2009 cohorts.  
135 Sum of cases may not add to 'total cases' due to rounding.

136



137  
138  
139

S: scenario; y: year.

140 **Figure 1:** Estimated lifetime HPV-related cancer cases from two HPV vaccination catch-up scenarios [(1-year  
141 delay in vaccination (rapid); 1 to 7 year delay in vaccination (slow))] and two scenarios modelling the absence of  
142 vaccination catch-up, varying in the cohort affected (scenario 3 affecting the 2008 birth cohort; scenario 4  
143 affecting the 2008 and 2009 birth cohorts).

144  
145

## 146 Discussion

147 This is the first study to estimate the long-term potential impact of missed HPV vaccinations across HPV-  
148 induced cancers while accounting for natural history, sexual behaviour and herd immunity. We found that  
149 rapid catch-up of HPV vaccination in young adolescents within a year meant that even extreme disruptions  
150 where all vaccinations were delayed had a minimal long-term effect on cancer cases. A slower pace of  
151 recovery, however, or, in the worst case, missed vaccination in one or two cohorts was associated with a higher  
152 excess burden of cancers. While herd effects from vaccination still prevented close to half of HPV-related  
153 cancers, missing a single cohort entirely would result in an estimated 49% more HPV-related cancers in that  
154 cohort compared to no disruption.

155

156 In Australia, for adolescents aged 11 to <15 years who received their first dose in 2020, 74.7% of girls and  
157 72.6% of boys, nationally, received their second dose in the same calendar year as their first dose.<sup>2</sup>  
158 Corresponding figures for 2019, for the second dose, were 86.2% and 84.3%, for girls and boys respectively.<sup>2</sup>  
159 The difference in numbers suggest vaccination delays, possibly due to COVID-19 effects including school  
160 closures during lockdowns, and decreased school attendance due to infections. Reports from other countries  
161 indicate that COVID-19 has delayed progress in achieving high coverage of HPV vaccination. For example, a US

162 study found recovery after a marked decline in HPV dose administration in March to May 2020 (median 64%-  
163 71%) was not fully achieved during June-September 2020.<sup>10</sup>

164  
165 In November 2020 WHO released a global strategy calling for all countries to take action to achieve the  
166 elimination of cervical cancer as a public health problem within the next century.<sup>11</sup> In the near future most  
167 lives will be saved globally through increased uptake of cervical screening and access to cancer treatment  
168 (Canfell 2020), but in the longer-term maintaining high coverage of HPV vaccination will be critical in reducing  
169 mortality and achieving global elimination.<sup>12,13</sup> Globally, the timeframe to reach elimination is likely to be  
170 impacted by pandemic-induced delays in HPV vaccination delivery and also by global shortages of the HPV  
171 vaccine estimated to last until 2024 thus delaying the introduction of vaccination in low- and middle-income  
172 countries.<sup>14</sup> In countries predicted to achieve cervical cancer elimination in the relatively short term, such as  
173 Australia, short delays of one year are not predicted to delay elimination.<sup>8</sup>

174  
175 The strengths of this study include evaluating the impact of the COVID-19 pandemic across different HPV-  
176 related cancers, in both women and men and across a wide range of possibilities for vaccination disruption -  
177 two of which assumed a delay in HPV vaccination and two scenarios where the affected birth cohorts remained  
178 unvaccinated. Some limitations should also be noted. Even in the context of some cohorts missing vaccination  
179 entirely, herd effects still prevented a considerable proportion of HPV-related cancers overall; these effects  
180 would be smaller in settings with lower coverage.<sup>15</sup> This is unlikely to affect our finding that catch-up within a  
181 year minimises the impact of disruptions, and so would likely strengthen the case for rapid catch-up in settings  
182 where herd effects are likely to be lower. The model also assumed that cervical screening would continue in  
183 birth cohorts offered HPV9, and, based on our sensitivity analysis that removed explicit modelling of screening,  
184 this prevented some cancers that would otherwise have occurred due to missed vaccination. In practice,  
185 screening may not continue in the same way in cohorts offered HPV9 as it would be much less cost-effective.<sup>16</sup>  
186 As yet, no policy decision has been made for screening in these cohorts, however, and screening may in future  
187 be tailored based on individual vaccination status, rather than age-eligibility for vaccination. The model did not  
188 incorporate any potential changes in sexual behaviour which may affect estimates.

189  
190 Our findings provide evidence that rapid catch-up of missed HPV vaccine doses would minimise the long-term  
191 impact of vaccination program disruptions, but delays would result in preventable HPV-related cancer cases in  
192 future.



## 193 **Competing Interests**

194 MAS reports salary support via fellowship grants from the National Health and Medical Research Council  
195 (NHMRC) of Australia (APP1159491) and Cancer Institute NSW (ECF181561) and contracts paid to her  
196 institution (the Daffodil Centre) with the Commonwealth Department of Health (Australia) and National  
197 Screening Unit (New Zealand). JMLB's former employer ACPC has received donated HPV tests and  
198 related items for validation and research purposes from Roche, Seegene, Abbott, Becton Dickinson,  
199 Cepheid and Copan. KC is co-PI of an investigator-initiated trial of cervical screening, "Compass", run by  
200 the Australian Centre for Prevention of Cervical Cancer (ACPC), which is a government-funded not-for-  
201 profit charity. Compass receives infrastructure support from the Australian government and the ACPC  
202 has received equipment and a funding contribution from Roche Molecular Diagnostics, USA. KC is also  
203 co-PI on a major implementation program Elimination of Cervical Cancer in the Western Pacific which  
204 has received support from the Minderoo Foundation and the Frazer Family Foundation and equipment  
205 donations from Cepheid Inc. KC receives contract funding from Commonwealth Department of Health,  
206 Australia to her institution for work to monitor the safety of the National Cervical Screening Program. KC  
207 also receives support for a range of other Australian and international government projects including  
208 support from philanthropic organizations, WHO, and government agencies related to cervical cancer  
209 control. The remaining authors have no conflicts of interests to declare.

210

## 211 **Data availability statement**

212 Supporting information on data, data sources, model parametrization, calibration to epidemiologic data, and  
213 calibration approach in line with good modeling practice can be found partly in the supplementary materials  
214 for this article and partly on-line (<https://www.policy1.org/models/cervix/documentation>). The current  
215 manuscript is a computational study involving modelling rather than direct analysis of primary datasets and no  
216 new datasets have been created.

217  
218 Code for the Policy1-cervix microsimulation model has been developed over decades, is proprietary property,  
219 and cannot be provided by the authors at this time. However, the Daffodil Centre is working to provide  
220 transparent and reproducible modelling code for forthcoming projects. Access to code is possible only through  
221 appropriately resourced supervision at the Daffodil Centre after submission and approval of a detailed proposal  
222 by the interested researcher. The corresponding author should be contacted in the first instance.

## 223 **References**

- 224 1. Australian Government Department of Health and Aged Care. National Immunisation Program  
225 Schedule: Government of Australia. [Accessed 5 August 2022].
- 226 2. National Centre for Immunisation Research and Surveillance Australia. Annual Immunisation Coverage  
227 Report 2020, 29 November 2021. (Accessed 8 August 2022). Available from:  
228 [https://www.ncirs.org.au/sites/default/files/2022-](https://www.ncirs.org.au/sites/default/files/2022-07/NCIRS%20Annual%20Immunisation%20Coverage%20Report%202020.pdf)  
229 [07/NCIRS%20Annual%20Immunisation%20Coverage%20Report%202020.pdf](https://www.ncirs.org.au/sites/default/files/2022-07/NCIRS%20Annual%20Immunisation%20Coverage%20Report%202020.pdf)
- 230 3. National Centre for Immunisation Research and Surveillance Australia. COVID-19 in schools and early  
231 childhood education and care services – the experience in NSW: 16 June to 31 July 2021. (Accessed 8  
232 August 2022). Available from: [https://www.ncirs.org.au/sites/default/files/2021-](https://www.ncirs.org.au/sites/default/files/2021-09/NCIRS%20NSW%20Schools%20COVID_Summary_8%20September%202021_Final.pdf)  
233 [09/NCIRS%20NSW%20Schools%20COVID\\_Summary\\_8%20September%202021\\_Final.pdf](https://www.ncirs.org.au/sites/default/files/2021-09/NCIRS%20NSW%20Schools%20COVID_Summary_8%20September%202021_Final.pdf)
- 234 4. Parliament of Victoria. Chronology of primary and secondary school closures in Victoria due to COVID-  
235 19, 3 April 2021. (Accessed on 8 August 2022). Research papers. Available from:

- 236 <https://www.parliament.vic.gov.au/publications/research-papers/send/36-research-papers/14000->  
237 [primary-and-secondary-school-closures-in-victoria-due-to-covid-19](https://www.parliament.vic.gov.au/publications/research-papers/send/36-research-papers/14000-)
- 238 5. World Health Organization. COVID-19 pandemic fuels largest continued backslide in vaccinations in  
239 three decades. 15 July 2022 (Accessed on 9 December 2022). Available from:  
240 [https://www.who.int/news/item/15-07-2022-covid-19-pandemic-fuels-largest-continued-backslide-in-](https://www.who.int/news/item/15-07-2022-covid-19-pandemic-fuels-largest-continued-backslide-in-vaccinations-in-three-decades)  
241 [vaccinations-in-three-decades](https://www.who.int/news/item/15-07-2022-covid-19-pandemic-fuels-largest-continued-backslide-in-vaccinations-in-three-decades)
- 242 6. IARC monographs on the evaluation of carcinogenic risks to Humans. A review of human carcinogens.  
243 Part B: Biological agents. Volume 100. Lyon, France: IARC; 2012. Accessed 9 August 2022. Available  
244 from: <https://monographs.iarc.who.int/wp-content/uploads/2018/06/mono100B.pdf>
- 245 7. Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, Marshall H. The impact of  
246 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a  
247 nonavalent vaccine prevent? *Euro Surveill.* 2018 Oct;23(41):1700737. doi: 10.2807/1560-  
248 7917.ES.2018.23.41.1700737.
- 249 8. Smith MA, Burger EA, Castanon A, de Kok IMCM, Hanley SJB, Rebolj M, Hall MT, Jansen EEL, Killen J,  
250 O'Farrell X, Kim JJ, Canfell K. Impact of disruptions and recovery for established cervical screening  
251 programs across a range of high-income country program designs, using COVID-19 as an example: A  
252 modelled analysis. *Prev Med.* 2021; 151:106623. doi: 10.1016/j.ypmed.2021.106623.
- 253 9. Kim JJ, Simms KT, Killen J, Smith MA, Burger EA, Sy S, Regan C, Canfell K. Human papillomavirus  
254 vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. *PLoS Med.*  
255 2021;18(3):e1003534. doi: 10.1371/journal.pmed.1003534.
- 256 10. Patel Murthy B, Zell E, Kirtland K, et al. Impact of the COVID-19 pandemic on administration of selected  
257 routine childhood and adolescent vaccinations - 10 U.S. Jurisdictions, March-September 2020. *MMWR*  
258 *Morb Mortal Wkly Rep.* 2021;70(23):840–845.
- 259 11. World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public  
260 Health Problem. November 2020. (Accessed 8 August 2022) Available from:  
261 <https://www.who.int/publications/i/item/9789240014107>
- 262 12. Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, et al. Mortality impact of achieving  
263 WHO cervical cancer elimination targets: A comparative modelling analysis in 78 low-income  
264 and lower-middle-income countries. *Lancet.* 2020;395(10224):591-603.
- 265 13. Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, Martin D, Simms KT, Bénard É, Boily  
266 MC, Sy S, Regan C, Keane A, Caruana M, Nguyen DTN, Smith MA, Laprise JF, Jit M, Alary M, Bray  
267 F, Fidarova E, Elsheikh F, Bloem PJN, Broutet N, Hutubessy R. Impact of HPV vaccination and  
268 cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-  
269 income and lower-middle-income countries. *Lancet.* 2020;395(10224):575-590.
- 270 14. World Health Organization (WHO). Global market study: HPV. Geneva: WHO; 2018. (Accessed  
271 <https://apps.who.int/iris/handle/10665/311275>)
- 272 15. Brisson M, Bénard É, Drolet M, Bogaards JA, Baussano I, Vänskä S, Jit M, Boily MC, Smith MA, Berkhof J,  
273 Canfell K, Chesson HW, Burger EA, Choi YH, De Blasio BF, De Vlas SJ, Guzzetta G, Hontelez JAC, Horn J,  
274 Jepsen MR, Kim JJ, Lazzarato F, Matthijse SM, Mikolajczyk R, Pavelyev A, Pillsbury M, Shafer LA, Tully  
275 SP, Turner HC, Usher C, Walsh C. Population-level impact, herd immunity, and elimination after human  
276 papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-  
277 dynamic models. *Lancet Public Health.* 2016;1(1):e8-e17.
- 278 16. Simms KT, Smith MA, Lew JB, Kitchener HC, Castle PE, Canfell K. Will cervical screening remain  
279 cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four  
280 developed countries. *Int J Cancer.* 2016;139(12):2771-2780. doi: 10.1002/ijc.30392.